Patent ID: 9005982
Filing Date: 2015-04-14
Classification: A01K,G01N

Abstract:
1. A method for assessing whether a mammalian patient has or is predisposed to an interstitial lung disease (ILD), said method comprising: a) performing an antibody-based assay to quantitate lung autoantigen-reactive autoantibodies in a biological sample from the patient, wherein the lung autoantigen is a long palate, lung, and nasal epithelium carcinoma-associated protein 1 (LPLUNC1) or a LPLUNC1-like protein comprising the amino acid sequence at least 70% identical to SEQ ID NO:2; and b) detecting an elevated level of the lung autoantigen-reactive autoantibodies in said biological sample as compared to a control biological sample thereby determining the patient has ILD or a predisposition to ILD.